2ldf: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
<table><tr><td colspan='2'>[[2ldf]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2LDF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2LDF FirstGlance]. <br> | <table><tr><td colspan='2'>[[2ldf]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2LDF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2LDF FirstGlance]. <br> | ||
</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2lde|2lde]]</td></tr> | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2lde|2lde]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2ldf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2ldf OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2ldf RCSB], [http://www.ebi.ac.uk/pdbsum/2ldf PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2ldf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2ldf OCA], [http://pdbe.org/2ldf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2ldf RCSB], [http://www.ebi.ac.uk/pdbsum/2ldf PDBsum]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/ | [[http://www.uniprot.org/uniprot/SRTXL_ATRMM SRTXL_ATRMM]] Vasoconstrictor activity. These toxins cause cardiac arrest probably as a result of coronary vasospasm. The major effects of sarafotoxin-m are a progressive decrease in heart rate (bradycardia) that turns into an arrhythmic phase that is followed by an A-V block.<ref>PMID:15350691</ref> Sarafotoxin-m: vasoconstrictor activity. Causes cardiac arrest probably as a result of coronary vasospasm (By similarity). Displays low agonistic activities towards endothelin-2 receptor (EDNRB) (displays affinity in the micromolar range) (PubMed:21889567).<ref>PMID:15350691</ref> <ref>PMID:21889567</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 16: | Line 16: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 2ldf" style="background-color:#fffaf0;"></div> | |||
== References == | == References == | ||
<references/> | <references/> | ||
